Developer docs
API playgroundTry for free, no card

Search company profiles

Quell

Full company profile

uuid000mk16

Namestring
Quell
Legal namestring
NeuroMetrix, Inc.
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Quell is a wearable pain relief technology brand operated by NeuroMetrix, Inc., a wholly-owned subsidiary of electroCore, Inc. since the May 2025 acquisition. The core product is a Transcutaneous Electrical Nerve Stimulation (TENS) device worn on the upper calf that delivers safe, painless electrical impulses to sensory nerves to trigger a natural pain relief response. Quell received FDA 510(k) Clearance (K152954) in 2015, with explicit labeling permitting use during sleep — a regulatory distinction versus standard TENS devices. The portfolio includes the now-discontinued original Quell, the current-generation Quell 2.0 (with smartphone-app-based calibration, sleep, gait, and pain-tracking features), and the prescription-only Quell Fibromyalgia variant targeting fibromyalgia patients. The proprietary dimethylacrylamide-based hydrogel electrode is latex-, BPA-, and phthalate-free, and integrates with Apple Health and Samsung Health for longitudinal data sync.

Quell monetizes via direct-to-consumer hardware sales through its online store and, post-acquisition, through institutional sales into the VA hospital system via parent electroCore's federal healthcare channel. Pricing is not publicly disclosed; a 60-day money-back guarantee is offered. Customer segments are chronic pain patients (consumer) and veterans within the VA healthcare system (institutional). electroCore reported Quell contributed $1.5M in revenue post-acquisition, with the broader company projecting approximately 30% full-year 2026 revenue growth driven by VA penetration and a 93% surge in complementary Truvaga wellness sales. Leadership is in transition: electroCore CEO Daniel Goldberger will retire April 1, 2026, succeeded by COO Michael Fox to leverage federal healthcare expertise. Quell's competitive position rests on its FDA sleep-use clearance, proprietary electrode chemistry, individual calibration, and now its parent's federal-channel reach rather than on AI or software differentiation.

Short descriptiontext

Quell is a wearable TENS pain relief device brand operated by NeuroMetrix (a subsidiary of electroCore), serving chronic pain patients via DTC online sales and VA hospital system distribution, with FDA clearance for overnight use.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
wearable pain relief, TENS therapy device, chronic pain management, nerve stimulation technology, neuromodulation device
Industry2 codes
SECONDARYCRACAQAK
Posture, Musculoskeletal & Pain-Relief Devices (Posture Trainers, TENS/EMS, Massage Devices)
Consumer Products & Retail/Consumer Electronics & Appliances Retail/Personal Health & Wellness Devices (Smart Scales, BP/ECG Monitors, Sleep Devices)
SECONDARYHLAHAEAK
Implantable Neuromodulation & Neurostimulation (SCS/DBS/VNS/PNS)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Wearable TENS Pain Relief Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Quell Product Sales
TypeHardware Sales
Description

electroCore acquired Quell assets in May 2025, contributing $1.5 million in revenue to the company. The acquisition expanded electroCore's product portfolio within the VA hospital system.

finance.yahoo.com
2Truvaga Wellness Sales
TypeHardware Sales
Description

93% surge in Truvaga wellness sales driven alongside Quell product line expansion in VA hospital system.

finance.yahoo.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Quell 2.0
Description

Second generation wearable pain relief device with advanced calibration and tracking features.

support.quellrelief.com
+1 more record
Core offering1 text field

Quell designs, manufactures, and sells wearable Transcutaneous Electrical Nerve Stimulation (TENS) devices worn on the upper calf that deliver electrical pulses to sensory nerves to trigger the body's natural pain relief response for chronic pain sufferers. The product portfolio includes the original Quell, the enhanced Quell 2.0, and the prescription-only Quell Fibromyalgia, all FDA 510(k) cleared (K152954) with companion smartphone app integration for therapy, sleep, and gait tracking.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 93% surge in Truvaga wellness sales
+2 more records
Product overview1 text field

Quell is a wearable pain relief technology platform by NeuroMetrix (a wholly-owned subsidiary of electroCore, Inc.) offering transcutaneous electrical nerve stimulation (TENS) devices for chronic pain management. The product portfolio includes the original Quell, Quell 2.0 (enhanced version), and Quell Fibromyalgia (prescription-only variant for fibromyalgia). All devices are worn on the upper calf and work via smartphone app connectivity for calibration, therapy tracking, and sleep monitoring.

Product and service3 records
1Quell (original)
CategoryCore product (wearable TENS device)
Description

Original wearable transcutaneous electrical nerve stimulation (TENS) device worn on the upper calf for chronic pain relief, with FDA 510(k) clearance, smartphone app connectivity, sleep tracking, and pain rating features. Listed as Discontinued on the Quell support site.

2Quell 2.0
CategoryCore product (wearable TENS device)
Description

Enhanced second-generation wearable TENS device for chronic pain management, including app-based calibration, therapy tracking, gait monitoring, sleep position tracking, and repetitive leg movement monitoring.

3Quell Fibromyalgia
CategoryPrescription medical device
Description

Prescription-only version of the Quell wearable TENS device specifically indicated for the treatment of fibromyalgia. Available exclusively by prescription through the dedicated quellfibromyalgia.com channel.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development Partner
Description

electroCore, Inc. completed the acquisition of Quell assets in May 2025. Quell assets are now part of electroCore's product portfolio, with NeuroMetrix operating as a wholly-owned subsidiary under electroCore ownership.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Omron Healthcare
TypeDirect peer
Description

Omron manufactures and sells consumer TENS devices such as the Omron Pocket Pain Pro and Electrotherapy Pain Relief units. Direct competitor to Quell in the OTC wearable TENS category for chronic and acute pain.

TypeDirect peer
Description

Hollywog sells the iTENS, a wireless, app-controlled wearable TENS unit for chronic pain. Highly comparable to Quell in product form factor, app integration, and direct-to-consumer channel.

TypeDirect peer
Description

BioElectronics produces ActiPatch and RecoveryRx, consumer-facing wearable pain relief devices using PEMF and pulsed electromagnetic therapy. Competes with Quell for the same chronic pain consumer looking for non-drug, OTC solutions.

TypeDirect peer
Description

Cala Health offers Cala Trio, a wearable transcutaneous afferent patterned stimulation (TAPS) device for essential tremor and is expanding into other neurological indications. Closely comparable to Quell as a prescription-grade, app-connected wearable neurostimulator sold outside the hospital.

TypeDirect peer
Description

ZetrOZ Systems sells sam, a wearable, FDA-cleared long-duration ultrasound device for musculoskeletal pain. Comparable to Quell as a non-pharmacological, wearable, app-connected pain relief device targeting chronic pain patients.

TypeDirect peer
Description

Avacen manufactures the Avacen 100, an FDA-cleared noninvasive medical device for chronic pain using thermal stimulation. Comparable to Quell as a non-drug, non-implantable, in-home pain relief device.

TypeBroad incumbent
Description

Chattanooga, part of Enovis (formerly DJO), is a long-standing manufacturer of clinical and consumer TENS/EMS units including the Intelect series. Overlaps with Quell in TENS technology but operates across a broader portfolio of orthopedic rehab and pain management products.

TypeBroad incumbent
Description

SPR Therapeutics commercializes the Sprint PNS system, a minimally invasive peripheral nerve stimulation platform for chronic and post-surgical pain. Comparable to Quell as a neuromodulation-based pain therapy, though SPR is implant-procedure-based while Quell is fully external.

TypeBroad incumbent
Description

electroCore is Quell's parent company following the May 2025 asset acquisition and sells gammaCore (nVNS) for headache and other indications. Relevant as the strategic acquirer and channel provider, with overlapping non-invasive neuromodulation positioning.

TypeEmerging player
Description

Saluda Medical is developing the Evoke closed-loop spinal cord stimulation system for chronic pain. Comparable to Quell as a chronic-pain neuromodulation competitor, though Saluda is an implantable SCS player versus Quell's transcutaneous approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

Integration2 records

Each record includes

Title, Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quell

Wearable TENS Pain Relief Devicessupport.quellrelief.com

Quell is a wearable TENS pain relief device brand operated by NeuroMetrix (a subsidiary of electroCore), serving chronic pain patients via DTC online sales and VA hospital system distribution, with FDA clearance for overnight use.

What Quell does

Quell is a wearable pain relief technology brand operated by NeuroMetrix, Inc., a wholly-owned subsidiary of electroCore, Inc. since the May 2025 acquisition. The core product is a Transcutaneous Electrical Nerve Stimulation (TENS) device worn on the upper calf that delivers safe, painless electrical impulses to sensory nerves to trigger a natural pain relief response. Quell received FDA 510(k) Clearance (K152954) in 2015, with explicit labeling permitting use during sleep — a regulatory distinction versus standard TENS devices. The portfolio includes the now-discontinued original Quell, the current-generation Quell 2.0 (with smartphone-app-based calibration, sleep, gait, and pain-tracking features), and the prescription-only Quell Fibromyalgia variant targeting fibromyalgia patients. The proprietary dimethylacrylamide-based hydrogel electrode is latex-, BPA-, and phthalate-free, and integrates with Apple Health and Samsung Health for longitudinal data sync.

Quell monetizes via direct-to-consumer hardware sales through its online store and, post-acquisition, through institutional sales into the VA hospital system via parent electroCore's federal healthcare channel. Pricing is not publicly disclosed; a 60-day money-back guarantee is offered. Customer segments are chronic pain patients (consumer) and veterans within the VA healthcare system (institutional). electroCore reported Quell contributed $1.5M in revenue post-acquisition, with the broader company projecting approximately 30% full-year 2026 revenue growth driven by VA penetration and a 93% surge in complementary Truvaga wellness sales. Leadership is in transition: electroCore CEO Daniel Goldberger will retire April 1, 2026, succeeded by COO Michael Fox to leverage federal healthcare expertise. Quell's competitive position rests on its FDA sleep-use clearance, proprietary electrode chemistry, individual calibration, and now its parent's federal-channel reach rather than on AI or software differentiation.

Quell firmographics

Firmographics
Name
Quell
Legal name
NeuroMetrix, Inc.
Website
https://support.quellrelief.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Quell is a wearable TENS pain relief device brand operated by NeuroMetrix (a subsidiary of electroCore), serving chronic pain patients via DTC online sales and VA hospital system distribution, with FDA clearance for overnight use.
Ownership category
akta.pro rank

Where Quell is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Quell business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Quell Product Sales: electroCore acquired Quell assets in May 2025, contributing $1.5 million in revenue to the company. The acquisition expanded electroCore's product portfolio within the VA hospital system.
  2. Truvaga Wellness Sales: 93% surge in Truvaga wellness sales driven alongside Quell product line expansion in VA hospital system.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Quell product offering

Product offering

Core offering

Quell designs, manufactures, and sells wearable Transcutaneous Electrical Nerve Stimulation (TENS) devices worn on the upper calf that deliver electrical pulses to sensory nerves to trigger the body's natural pain relief response for chronic pain sufferers. The product portfolio includes the original Quell, the enhanced Quell 2.0, and the prescription-only Quell Fibromyalgia, all FDA 510(k) cleared (K152954) with companion smartphone app integration for therapy, sleep, and gait tracking.

Product overview

Quell is a wearable pain relief technology platform by NeuroMetrix (a wholly-owned subsidiary of electroCore, Inc.) offering transcutaneous electrical nerve stimulation (TENS) devices for chronic pain management. The product portfolio includes the original Quell, Quell 2.0 (enhanced version), and Quell Fibromyalgia (prescription-only variant for fibromyalgia). All devices are worn on the upper calf and work via smartphone app connectivity for calibration, therapy tracking, and sleep monitoring.

Differentiator

Problem solved

Functional benefit

Brands

  • Quell 2.0: Second generation wearable pain relief device with advanced calibration and tracking features.
  • Quell Fibromyalgia

Products and services

  • Quell (original) Original wearable transcutaneous electrical nerve stimulation (TENS) device worn on the upper calf for chronic pain relief, with FDA 510(k) clearance, smartphone app connectivity, sleep tracking, and pain rating features. Listed as Discontinued on the Quell support site.
  • Quell 2.0 Enhanced second-generation wearable TENS device for chronic pain management, including app-based calibration, therapy tracking, gait monitoring, sleep position tracking, and repetitive leg movement monitoring.
  • Quell Fibromyalgia Prescription-only version of the Quell wearable TENS device specifically indicated for the treatment of fibromyalgia. Available exclusively by prescription through the dedicated quellfibromyalgia.com channel.

Quantifiable outcome

  • 93% surge in Truvaga wellness sales
  • +2 more outcomes

Companies that use Quell

Customer profile

Segments2 records

Ideal customer profiles3 records

Quell technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Integration2 records

Feature5 records

Quell partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • electroCore, Inc.coreStrategic or Co-development PartnerelectroCore, Inc. completed the acquisition of Quell assets in May 2025. Quell assets are now part of electroCore's product portfolio, with NeuroMetrix operating as a wholly-owned subsidiary under electroCore ownership.

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Quell competitors and assessment

Company assessment

Direct peers

  • Omron Healthcare: Omron manufactures and sells consumer TENS devices such as the Omron Pocket Pain Pro and Electrotherapy Pain Relief units. Direct competitor to Quell in the OTC wearable TENS category for chronic and acute pain.
  • Hollywog: Hollywog sells the iTENS, a wireless, app-controlled wearable TENS unit for chronic pain. Highly comparable to Quell in product form factor, app integration, and direct-to-consumer channel.
  • BioElectronics Corporation: BioElectronics produces ActiPatch and RecoveryRx, consumer-facing wearable pain relief devices using PEMF and pulsed electromagnetic therapy. Competes with Quell for the same chronic pain consumer looking for non-drug, OTC solutions.
  • Cala Health: Cala Health offers Cala Trio, a wearable transcutaneous afferent patterned stimulation (TAPS) device for essential tremor and is expanding into other neurological indications. Closely comparable to Quell as a prescription-grade, app-connected wearable neurostimulator sold outside the hospital.
  • ZetrOZ Systems: ZetrOZ Systems sells sam, a wearable, FDA-cleared long-duration ultrasound device for musculoskeletal pain. Comparable to Quell as a non-pharmacological, wearable, app-connected pain relief device targeting chronic pain patients.
  • Avacen Medical: Avacen manufactures the Avacen 100, an FDA-cleared noninvasive medical device for chronic pain using thermal stimulation. Comparable to Quell as a non-drug, non-implantable, in-home pain relief device.

Broad incumbents

  • Chattanooga (DJO Global / Enovis): Chattanooga, part of Enovis (formerly DJO), is a long-standing manufacturer of clinical and consumer TENS/EMS units including the Intelect series. Overlaps with Quell in TENS technology but operates across a broader portfolio of orthopedic rehab and pain management products.
  • SPR Therapeutics: SPR Therapeutics commercializes the Sprint PNS system, a minimally invasive peripheral nerve stimulation platform for chronic and post-surgical pain. Comparable to Quell as a neuromodulation-based pain therapy, though SPR is implant-procedure-based while Quell is fully external.
  • electroCore: electroCore is Quell's parent company following the May 2025 asset acquisition and sells gammaCore (nVNS) for headache and other indications. Relevant as the strategic acquirer and channel provider, with overlapping non-invasive neuromodulation positioning.

Emerging players

  • Saluda Medical: Saluda Medical is developing the Evoke closed-loop spinal cord stimulation system for chronic pain. Comparable to Quell as a chronic-pain neuromodulation competitor, though Saluda is an implantable SCS player versus Quell's transcutaneous approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key highlights7 records

Customer concentration

Quell compliance and trust

Trust signal

Compliance1 record

Quell financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quell leadership team

Management profile

Number of profiles

Profiles4 records

Quell funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quell M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quell

What does Quell do?

Quell designs, manufactures, and sells wearable Transcutaneous Electrical Nerve Stimulation (TENS) devices worn on the upper calf that deliver electrical pulses to sensory nerves to trigger the body's natural pain relief response for chronic pain sufferers. The product portfolio includes the original Quell, the enhanced Quell 2.0, and the prescription-only Quell Fibromyalgia, all FDA 510(k) cleared (K152954) with companion smartphone app integration for therapy, sleep, and gait tracking.

Is Quell a public or private company?

Quell is a private company. It is classified as corporate owned and is currently operating.

When was Quell founded?

Quell was founded in 2015. It employs 11 to 50 people.

Where is Quell based?

Quell is headquartered in Waltham, United States, in the North America region.

How does Quell make money?

Two revenue lines are on record. Quell Product Sales are the primary driver. The others are truvaga Wellness Sales.

Who are Quell's main competitors?

Direct peers on record are Omron Healthcare, Hollywog, BioElectronics Corporation, Cala Health, ZetrOZ Systems and Avacen Medical. Broad incumbents are Chattanooga (DJO Global / Enovis), SPR Therapeutics and electroCore. Saluda Medical is listed as an emerging player.

Does Quell have an API?

No public API is recorded for Quell.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals